Takara has been granted a patent for methods of producing product nucleic acids using modified oligonucleotides that can be activated or deactivated by specific stimuli. The patent also covers kits, compositions, and devices for performing these methods. GlobalData’s report on Takara gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Takara, anti-viral antigen-based compositions was a key innovation area identified from patents. Takara's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Method for producing product nucleic acids using modified oligonucleotides
A recently granted patent (Publication Number: US11667952B2) describes a method for elongating and deactivating oligonucleotides, which are short DNA or RNA molecules. The method involves using a template nucleic acid-mediated primer extension reaction to elongate the oligonucleotide and then irreversibly deactivating it.
The deactivation of the oligonucleotide can be achieved through various stimuli, including enzymes, chemical agents, or electromagnetic stimuli. In one specific embodiment, the enzyme ribonuclease H (RNase H) is used as the deactivating stimulus.
The method also includes a template switching reaction, which involves using a template switching oligonucleotide (TSO) to produce an extended nucleic acid that contains a sequence complementary to the TSO. The TSO itself can be deactivatable.
Furthermore, the deactivatable oligonucleotide, TSO, or both can contain adapter sequences, barcode sequences, or a combination thereof.
The method may also involve amplifying the extended nucleic acid and performing a tagmentation reaction, which is a process that combines fragmentation and tagging of DNA molecules.
The deactivating stimulus can be an enzyme, a chemical agent, or an electromagnetic stimulus. In the case of an electromagnetic stimulus, light is specifically mentioned.
Deactivating the deactivatable oligonucleotide can involve selectively cleaving one or more selectively cleavable linkages present in the oligonucleotide, resulting in multiple fragments.
The deactivation of the oligonucleotide destroys its pre-deactivation function. However, the deactivated oligonucleotide can still be present in a later reaction without interfering with downstream reaction steps.
Finally, the deactivatable oligonucleotide can be deactivated in its unhybridized state, its hybridized state, or both.
Overall, this patent describes a method for elongating and deactivating oligonucleotides using various stimuli, such as enzymes, chemical agents, or electromagnetic stimuli. The method also includes template switching reactions, amplification, tagmentation, and selective cleavage of linkages. The deactivation of the oligonucleotide allows for its presence in subsequent reactions without interfering with downstream steps.
To know more about GlobalData’s detailed insights on Takara, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
